Arcellx (NASDAQ:ACLX) Reaches New 52-Week High – Still a Buy?

01 Apr 2026, 18:18 by Michael Walen · The Markets Daily

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) shares reached a new 52-week high on Wednesday . The stock traded as high as $114.94 and last traded at $114.8950, with a volume of 455581 shares. The stock had previously closed at $114.82.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. TD Cowen lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. Needham & Company LLC cut Arcellx from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Guggenheim lowered Arcellx from a “buy” rating to a “neutral” rating and dropped their price target for the company from $120.00 to $115.00 in a research note on Wednesday, February 25th. Finally, Truist Financial raised shares of Arcellx from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Arcellx currently has a consensus rating of “Hold” and a consensus target price of $111.87.

Get Our Latest Analysis on ACLX

Arcellx Price Performance

The stock has a fifty day moving average price of $93.18 and a two-hundred day moving average price of $82.91. The company has a market cap of $6.71 billion, a P/E ratio of -28.21 and a beta of 0.23.

Arcellx (NASDAQ:ACLX – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.01). The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%. Equities analysts predict that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the transaction, the insider directly owned 276,051 shares of the company’s stock, valued at $31,447,729.92. This trade represents a 24.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Heery sold 7,437 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the transaction, the insider owned 29,631 shares in the company, valued at approximately $1,941,126.81. This trade represents a 20.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 109,366 shares of company stock worth $11,526,708 over the last ninety days. Insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Arcellx

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACLX. T. Rowe Price Investment Management Inc. lifted its position in shares of Arcellx by 66.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company’s stock worth $688,540,000 after buying an additional 4,208,069 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Arcellx by 134.0% in the fourth quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock valued at $190,710,000 after acquiring an additional 1,675,000 shares in the last quarter. Paradigm Biocapital Advisors LP increased its position in shares of Arcellx by 23.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 5,724,016 shares of the company’s stock valued at $373,206,000 after acquiring an additional 1,075,000 shares during the last quarter. Decheng Capital LLC lifted its holdings in Arcellx by 995.2% during the second quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock worth $36,060,000 after acquiring an additional 497,609 shares during the period. Finally, State Street Corp lifted its holdings in Arcellx by 31.0% during the fourth quarter. State Street Corp now owns 1,998,503 shares of the company’s stock worth $130,302,000 after acquiring an additional 472,476 shares during the period. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Arcellx Company Profile

(Get Free Report)

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.